sprite-preloader
Anzeige
Mehr »
Montag, 28.05.2018 Börsentäglich über 12.000 News von 579 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A12HQS ISIN: US84652J1034 Ticker-Symbol: 272 
Aktie:
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SPARK THERAPEUTICS INC Chart 1 Jahr
1-Woche-Intraday-Chart
SPARK THERAPEUTICS INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
66,68
67,69
27.05.
66,76
67,71
25.05.
13.02.2018 | 13:40
(6 Leser)
Schrift ändern:
(0 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 20, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the year that ended Dec. 31, 2017 and recent business highlights.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 9596288. To access a live audio webcast, please visit the "Investors" section at www.sparktx.com (http://www.sparktx.com/).

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 9596288, or by visiting the "Investors" section at www.sparktx.com (http://www.sparktx.com/).

About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com (http://www.sparktx.com/), and follow us on Twitter (https://twitter.com/spark_tx) and LinkedIn (https://www.linkedin.com/company/spark-therapeutics-inc).

Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com (mailto:Ryan.asay@sparktx.com)
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com (mailto:Monique.dasilva@sparktx.com)
(215) 282-7470



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Spark Therapeutics, Inc. via Globenewswire


© 2018 GlobeNewswire (Europe)